Open AccessA regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines
Author(s) -
Alex Price-Forbes,
Robert C. Callaghan,
Maggie Allen,
I. F. Rowe
Publication year - 2005
Publication title -
rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.957
H-Index - 173
eISSN - 1462-0332
pISSN - 1462-0324
DOI - 10.1093/rheumatology/keh642
Subject(s) - medicine , rheumatology , rofecoxib , meloxicam , celecoxib , rheumatoid arthritis , medical prescription , adverse effect , etanercept , nice , osteoarthritis , proportional hazards model , alternative medicine , pharmacology , cyclooxygenase , biochemistry , chemistry , programming language , pathology , computer science , enzyme
Whilst all non-steroidal anti-inflammatory drugs (NSAIDs) can cause adverse gastrointestinal events, COX-2-selective inhibitors (COX-2) may have improved gastrointestinal safety compared with non-selective NSAIDs (NSNSAIDs). In 2001, the National Institute for Clinical Excellence (NICE) published guidance on the use of the COX-2 agents celecoxib, rofecoxib, meloxicam and etodolac for rheumatoid arthritis (RA) and osteoarthritis (OA). This study aimed to audit the appropriateness of NSAID use in relation to NICE guidance in rheumatology out-patients.